One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Timing, Selection, Modulation, and Duration of P2Y12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing PCI
Davide Capodanno, MD,a Dominick J. Angiolillo, MD, PHD
doi : 10.1016/j.jcin.2022.10.023
Volume 16, Issue 1, 9 January 2023, Pages 1-18
Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) was firstly established in 2001.
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention
Ko Yamamoto, MD, a, * Hirotoshi Watanabe, MD, a, * Takeshi Morimoto, MD, MPH, b Yuki Obayashi, MD,a Masahiro Natsuaki, MD,c Kyohei Yamaji, MD, a Takenori Domei, MD,d Manabu Ogita, MD, e Masanobu Ohya, MD, f Shojiro Tatsushima, MD, g Hirohiko Suzuki, MD, h Tomohisa Tada, MD,i Mitsuru Ishii, MD,j Akira Nikaido, MD,k Naoki Watanabe, MD,l Shinya Fujii, MD,m Hiroyoshi Mori, MD, n Tenjin Nishikura, MD,o Nobuhiro Suematsu, MD,p Fujio Hayashi, MD,q Kota Komiyama, MD,r Tatsuya Shigematsu, MD,s Tsuyoshi Isawa, MD,t Satoru Suwa, MD, e Kenji Ando, MD,d Takeshi Kimura, MD, a on behalf of the STOPDAPT-2 and STOPDAPT-2 ACS Investigators
doi : 10.1016/j.jcin.2022.09.053
Volume 16, Issue 1, 9 January 2023, Pages 19-31
Diabetes was reported to be associated with an impaired response to clopidogrel.
Clopidogrel Monotherapy After 1-Month DAPT in Diabetic Patients Undergoing PCI: Is Less Always More?
Davide Cao, MD, a,b Felice Gragnano, MD, PHD
doi : 10.1016/j.jcin.2022.10.044
Volume 16, Issue 1, 9 January 2023, Pages 32-35
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study
Francesco Franchi, MD,a Luis Ortega-Paz, MD, PHD, a Fabiana Rollini, MD,a Mattia Galli, MD, a,b Latonya Been, AAS, a Ghussan Ghanem, MD,a Awss Shalhoub, MD,a Tiffany Ossi, MD, a Andrea Rivas, MD, a Xuan Zhou, MD,a Andres M. Pineda, MD, a Siva Suryadevara, MD,a Daniel Soffer, MD, a Martin M. Zenni, MD, a Birgit Reiter, P HD, c Bernd Jilma, MD, d Dominick J. Angiolillo, MD, PH D a
doi : 10.1016/j.jcin.2022.10.034
Volume 16, Issue 1, 9 January 2023, Pages 36-46
There are no studies specifically designed to rule out a drug-drug interaction (DDI) when cangrelor is used among patients who have been pretreated with ticagrelor.
Switching Between Intravenous and Oral P2Y12 Inhibition: Easier Said Than Done
Usman Baber, MD, MS
doi : 10.1016/j.jcin.2022.11.014
Volume 16, Issue 1, 9 January 2023, Pages 47-49
Simultaneous Hybrid Coronary Revascularization vs Conventional Strategies for Multivessel Coronary Artery Disease: A 10-Year Follow-Up
Tong Ding, MD, PHD, a,b, * Xin Yuan, MD, P HD, a,b, * Kai Chen, MD, PH D, a,b Liuzhong Shen, MD, a,b Changdong Guan, MS C, a,c Feng Lv, MD, a,b Hui Xiong, MD,a,b Bo Xu, MBSS,a,c Yongjian Wu, MD,a,d Shengshou Hu, MD
doi : 10.1016/j.jcin.2022.09.049
Volume 16, Issue 1, 9 January 2023, Pages 50-60
Although evidence is sufficient to confirm that hybrid coronary revascularization (HCR) is safe and effective in the short term, its value in the long run is debatable.
Hybrid Coronary Revascularization: Best of 2 Worlds in the Environment Where Revascularization Is in Reverse
Mateusz Tajstra, MD, P HD, Krzysztof Wilczek, MD, PHD, Mariusz Ga ̨sior, MD, P HD
doi : 10.1016/j.jcin.2022.11.001
Volume 16, Issue 1, 9 January 2023, Pages 61-63
Early Invasive Strategy Based on the Time of Symptom Onset of Non-ST-Segment Elevation Myocardial Infarction
SungA Bae, MD, a,b, * Jung-Joon Cha, MD,c, * Subin Lim, MD,c Ju Hyeon Kim, MD,c Hyung Joon Joo, MD,c Jae Hyoung Park, MD, c Soon Jun Hong, MD,c Cheol Woong Yu, MD, c Do-Sun Lim, MD,c Yongcheol Kim, MD,a,b Woong Chol Kang, MD, d Eun Jeong Cho, MD, e Sang Yeub Lee, MD,e Sang Wook Kim, MD,e Eun-Seok Shin, MD, f Seung Ho Hur, MD, g Seok Kyu Oh, MD,h Seong-Hoon Lim, MD,i Hyo-Soo Kim, MD, j Young Joon Hong, MD, a Youngkeun Ahn, MD, a Myung Ho Jeong, MD,a Tae Hoon Ahn, MD
doi : 10.1016/j.jcin.2022.09.039
Volume 16, Issue 1, 9 January 2023, Pages 64-75
A limitation of the current guidelines regarding the timing of invasive coronary angiography for patients with non–ST-segment elevation acute coronary syndrome is the randomization time. To date, no study has reported the clinical outcomes of invasive strategy timing on the basis of the time of symptom onset.
Timing of Invasive Coronary Angiography in NSTEMI
Jean-Philippe Collet, MD,a Sripal Bangalore, MD, MHA b
doi : 10.1016/j.jcin.2022.10.043
Volume 16, Issue 1, 9 January 2023, Pages 76-78
No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry
Yusuke Kobari, MD, a Taku Inohara, MD, a Hikaru Tsuruta, MD,a Fumiaki Yashima, MD, a,b Hideyuki Shimizu, MD, a Keiichi Fukuda, MD, a Toru Naganuma, MD,c Kazuki Mizutani, MD,d Masahiro Yamawaki, MD,e Norio Tada, MD, f Futoshi Yamanaka, MD, g Shinichi Shirai, MD, h Minoru Tabata, MD,i Hiroshi Ueno, MD, j Kensuke Takagi, MD,k Yusuke Watanabe, MD,l Masanori Yamamoto, MD,m,n Kentaro Hayashida, MD
doi : 10.1016/j.jcin.2022.10.010
Volume 16, Issue 1, 9 January 2023, Pages 79-91
Several trials demonstrated that aspirin monotherapy compared with aspirin plus clopidogrel is associated with a lower incidence of bleeding without an increased risk of ischemic events in patients after transcatheter aortic valve replacement (TAVR); however, there remains a paucity of data to prove the necessity of even aspirin monotherapy.
Antithrombotic After TAVR: No Treatment, No Problem?
Vincent Auffret, MD, P HD, a Paul Guedeney, MD, b Guillaume Leurent, MD,a Romain Didier, MD, P HD
doi : 10.1016/j.jcin.2022.11.003
Volume 16, Issue 1, 9 January 2023, Pages 92-93
First-in-Human Dedicated Leaflet Splitting Device for Prevention of Coronary Obstruction in Transcatheter Aortic Valve Replacement
Danny Dvir, MD, a Martin B. Leon, MD, b Mohamed Abdel-Wahab, MD,c Axel Unbehaun, MD, d Susheel Kodali, MD,e Didier Tchetche, MD,f Philippe Pibarot, MD,g Jonathon Leipsic, MD,h Philipp Blanke, MD, h Ulrich Gerckens, MD,i Ganesh Manoharan, MD, j Emanuel Harari, MD,k Elias Hellou, MD, l Arik Wolak, MD, a Eyal Ben-Assa, MD,m,n Rami Jubeh, MD, l Mony Shuvy, MD,a Edward Koifman, MD, o,p Christoph Klein, MD,d Joerg Kempfert, MD
doi : 10.1016/j.jcin.2022.10.050
Volume 16, Issue 1, 9 January 2023, Pages 94-102
Coronary artery obstruction is a life-threatening complication of transcatheter aortic valve replacement (TAVR) procedures. Current preventive strategies are suboptimal.
Is There a Shortcut to Leaflet Splitting?
Toby Rogers, MD, PHD
doi : 10.1016/j.jcin.2022.11.016
Volume 16, Issue 1, 9 January 2023, Pages 103-105
Mechanical Circulatory Support via Percutaneous Transcarotid Access for High-Risk Percutaneous Coronary Intervention
Lorenzo Azzalini, MD, P HD, MS C, Gregory Condos, MD, Kathleen E. Kearney, MD, William L. Lombardi, MD, James M. McCabe, MD
doi : 10.1016/j.jcin.2022.09.038
Volume 16, Issue 1, 9 January 2023, Pages 106-108
Bailout Snorkel Technique Successfully Rescued the Left Main Coronary Artery During Transcatheter Aortic Valve Replacement
Naoya Yabumoto, MD, a Kensuke Takagi, MD, PHD, a Naonori Kawamoto, MD, b Teruo Noguchi, MD, PHD
doi : 10.1016/j.jcin.2022.10.021
Volume 16, Issue 1, 9 January 2023, Pages 109-111
EnVast Mechanical Thrombectomy After Thrombus Aspiration Failure in a STEMI With a Massive Thrombotic Burden
Dario Bongiovanni, MD,a,b Francesco Loizzi, MD, a Antonio Landi, MD, a Léa Utsch, MED V ET,c Marco Araco, MD,a Michael Joner, MD,c Marco Valgimigli, MD, PH D
doi : 10.1016/j.jcin.2022.09.050
Volume 16, Issue 1, 9 January 2023, Pages 112-115
Plaque Progression Secondary to Intraplaque Hemorrhage Associated With Coronary Vasospasm
Javier Cuesta, MD, Teresa Bastante, MD, David del Val, MD, Fernando Rivero, MD, Fernando Alfonso, MD
doi : 10.1016/j.jcin.2022.09.060
Volume 16, Issue 1, 9 January 2023, Pages 116-117
Balloon-Expandable Valve for Treatment of Self-Expanding Supra-Annular Valve Failure
Orazio Strazzieri, MD, Silvia Crescenzia Motta, MD, Giuliano Costa, MD, Roberto Valvo, MD, Claudia Reddavid, MD, Valentina Frittitta, MD, Elena Dipietro, MD, Chiara Melfa, MD, Alessandro Comis, MD, Carmelo Sgroi, MD, Corrado Tamburino, MD, PHD, Marco Barbanti, MD
doi : 10.1016/j.jcin.2022.09.056
Volume 16, Issue 1, 9 January 2023, Pages 118-119
Transcatheter Aortic Valve Replacement for Failed Valve Sparing Procedures
Nils Perrin, MD Silvia Corona, MD Valentin Loobuyck, MD Augustin Coisne, MD, PhD Arnaud Sudre, MD André Vincentelli, MD, PhD Francis Juthier, MD, PhD Lionel Leroux, MD Walid Ben Ali, MD, PhD* yThomas Modine, MD, PhD
doi : 10.1016/j.jcin.2022.09.033
Volume 16, Issue 1, 9 January 2023, Pages 120-122
Transcatheter Aortic Valve-in-Valve Replacement for Failed Sutureless Aortic Valves
Victoria Vilalta, MD Pablo Piñón, MD Juan GarcÃa de Lara, MD, PhD Xavier Millán, MD, PhD Rafael Romaguera, MD, PhD Xavier Carrillo, MD, PhD Eduard Fernández-NofrerÃas, MD Jose Montero-Cabezas, MD Victoria Delgado, MD, PhD Ignacio Cruz-Gonzalez, MD, PhD Antoni Bayés-GenÃs, MD, PhD *Josep Rodés-Cabau, MD, PhD
doi : 10.1016/j.jcin.2022.09.055
Volume 16, Issue 1, 9 January 2023, Pages 122-124
Multicenter Registry of Patients Treated With Impella Mechanical Circulatory Support Device in Italy: Sex Subanalysis
Alessandro Beneduce, MD Francesca Ziviello, MD Carlo Briguori, MD Carlo Trani, MD Elisa Nicolini, MD Giulia Masiero, MD Federico De Marco, MD Anna Mara Scandroglio, MD Giuseppe Tarantini, MD *Alaide Chieffo, MD
doi : 10.1016/j.jcin.2022.10.042
Volume 16, Issue 1, 9 January 2023, Pages 124-126
